Poor Physical Function Persists in Childhood Cancer Survivors
By Lori Solomon HealthDay Reporter
MONDAY, Nov. 20, 2023 -- Despite changes in therapy, the prevalence of poor physical function has remained steady among childhood survivors of acute lymphoblastic leukemia (ALL) and non-Hodgkin lymphoma (NHL), according to a study published online Nov. 8 in the Journal of Cancer Survivorship.
Carmen L. Wilson, from St. Jude Children's Research Hospital in Memphis, Tennessee, and colleagues examined the prevalence of reduced function among ALL and NHL survivors by treatment era. The analysis included 6,511 survivors of childhood ALL and NHL and a cohort of their siblings (4,127), participating in the Childhood Cancer Survivor Study.
The researchers found that risks for performance limitations (15.2 versus 12.5 percent; prevalence ratio [PR], 1.5), restrictions in personal care (2.0 versus 0.6 percent; PR, 3.1), routine activities (5.5 versus 1.6 percent; PR, 3.6), and work/school attendance (8.8 versus 2.1 percent; PR, 4.5) were increased in survivors compared with siblings. Between the 1970s and 1990s, the prevalence of survivors reporting reduced function did not decrease. Regardless of treatment decade, the presence of neurological and cardiovascular conditions was associated with reduced function.
"Our findings support screening for reduced physical function so that early interventions to improve physical performance and mitigate chronic disease can be initiated," the authors write.
Abstract/Full Text (subscription or payment may be required)
Disclaimer: Statistical data in medical articles provide general trends and do not pertain to individuals. Individual factors can vary greatly. Always seek personalized medical advice for individual healthcare decisions.
© 2024 HealthDay. All rights reserved.
Posted November 2023
Read this next
Immunoglobulin Replacement Therapy Beneficial for Blood Cancers
THURSDAY, June 27, 2024 -- Immunoglobulin replacement therapy (IgRT) is associated with reductions in hypogammaglobulinemia, infections, severe infections, and associated...
Glofitamab + GemOx Superior to Rituximab + GemOx for Lymphoma
WEDNESDAY, June 26, 2024 -- Glofitamab (Glofit) plus gemcitabine and oxaliplatin (GemOx) is superior to rituximab (R)-GemOx for relapsed/refractory (R/R) diffuse large B-cell...
Posttransplant Cyclophosphamide GVHD Prophylaxis Beneficial in Leukemia
MONDAY, June 24, 2024 -- For patients with acute myeloid leukemia (AML) undergoing allogeneic stem cell transplantation, posttransplant cyclophosphamide (PTCy)...
More news resources
- FDA Medwatch Drug Alerts
- Daily MedNews
- News for Health Professionals
- New Drug Approvals
- New Drug Applications
- Drug Shortages
- Clinical Trial Results
- Generic Drug Approvals
Subscribe to our newsletter
Whatever your topic of interest, subscribe to our newsletters to get the best of Drugs.com in your inbox.